Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Vaxneuvance by Year
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Merck Vaxneuvance: 1.0% in FY2025, down 22.0 pts from a year earlier.
Latest, FY2025
1.0%
Period ended Dec 31, 2025
Change on a year earlier
-22.0 pts
23.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Vaxneuvance | 230 | 229 | 226 | 140 | 825 | 219 | 189 | 239 | 161 | 808 | -13 | -16 | 2 | 1”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.0% | -22.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 23.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Merck Vaxneuvance (%), annual FY2024–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vaxneuvance-ww-exfx-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.